A series of recent cases of HER2 mutations in ER + BC patients following various anti-estrogen therapies have been reported, and in this series, one patient successfully reversed endocrine resistance with the addition of neratinib (Nayar et al. 2019). This evidence concerns the gene ERBB2 and breast cancer.